Tourmaline Oil Corp. closed 7.6% below its 52-week high of C$70.83, which the company reached on February 21st.

H.C. Wainwright raised the firm’s price target on Tourmaline Bio (TRML) to $50 from $49 and keeps a Buy rating on the shares following the Q4 ...

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total ...

Tourmaline Oil Corp. closed 10.1% short of its 52-week high of C$70.83, which the company reached on February 21st.

The market expects Tourmaline Oil Corp. (TRMLF) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known ...

Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued on Thursday, March 6th. Wedbush analyst L. Chico expects that the company will post ...

Tourmaline Oil remains Canada’s largest natural gas producer and continues to reward investors through both regular and ...

Read Our Latest Stock Analysis on TRML Tourmaline Bio Trading Down 1.2 % Tourmaline Bio stock opened at $12.79 on Wednesday. Tourmaline Bio has a 1-year low of $11.87 and a 1-year high of $48.31 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalinebio.com. DOWNLOAD THE ...